2型糖尿病合并肾性糖尿患者的临床与遗传特征
研究纳入2044例中国2型糖尿病患者,其中肾性糖尿64例、低尿糖排泄58例,检测空腹血浆与尿糖浓度并测序SLC5A2与HNF1A外显子。肾性糖尿患者较lowe尿糖排泄者更年轻、BMI与HOMA-IR更低、高血压更少;检出SLC5A2新突变V359G(32例)与HNF1A已知突变R131W(28例非肥胖肾性糖尿患者)。作者认为SLC5A2与HNF1A突变部分解释2型糖尿病患者的肾性糖尿。
要点
- 肾性糖尿患者较lowe尿糖排泄者更年轻、BMI与HOMA-IR更低、高血压更少。
- 调整年龄、性别、高血压与胰岛素治疗后,HOMA-IR与BMI与肾性糖尿负相关。
- SLC5A2突变V359G见于32例肾性糖尿患者,HNF1A突变R131W见于28例非肥胖肾性糖尿患者。
核心结论
- 作者认为2型糖尿病存在以不同尿糖排泄和心血管危险因素为特征的亚型,SLC5A2与HNF1A突变部分解释2型糖尿病患者的肾性糖尿。
研究设计与样本
- 共纳入2044例中国2型糖尿病患者,包括64例肾性糖尿患者和58例lowe尿糖排泄患者,检测空腹血浆与尿糖浓度,并对SLC5A2与HNF1A外显子进行测序。
主要发现
- 与lowe尿糖排泄患者相比,肾性糖尿患者更年轻(P=0.008)、BMI更低(P=0.002)、HOMA-IR更低(P<0.0001)、高血压更少(P=0.006)。
- 调整年龄、性别、高血压和胰岛素治疗后,HOMA-IR与BMI与肾性糖尿呈负相关。
- 在32例肾性糖尿患者中检出SLC5A2新突变V359G,在28例非肥胖肾性糖尿患者中检出HNF1A已知突变R131W。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: A sodium glucose cotransporter 2 (SGLT2) inhibitor, which increases urinary glucose excretion, was reported to decrease blood glucose levels and deaths among patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease. SLC5A2 and HNF1A mutations are associated with renal glycosuria, but their contributions to renal glycosuria in patients with T2DM are not well understood. OBJECTIVE: To assess the clinical features of patients with T2DM and renal glycosuria and those with T2DM and low urinary glucose excretion (LUGE) and identify variants in the exons of SLC5A2 and HNF1A in patients with renal glycosuria and T2DM. DESIGN: A total of 2044 Chinese patients with T2DM, including 64 patients with renal glycosuria and 58 patients with LUGE, were tested for their plasma and urine glucose concentrations after fasting. SLC5A2 and HNF1A exons were sequenced. RESULTS: Compared with patients with LUGE, those with renal glycosuria were younger (P = 0.008), had lower body mass index (BMI) (P = 0.002) and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values (P < 0.0001), and were less likely to have hypertension (P = 0.006). HOMA-IR and BMI were negatively associated with renal glycosuria after adjusting for age, sex, hypertension, and insulin therapy. One novel mutation (V359G) of SLC5A2 in 32 patients with renal glycosuria and one known mutation (R131W) of HNF1A in 28 nonobese patients with renal glycosuria were identified. CONCLUSIONS: These findings suggest that there are subtypes of T2DM characterized by different urinary glucose excretion and cardiovascular risk factors. SLC5A2 and HNF1A mutations partially explain renal glycosuria in patients with T2DM.
引用
- Gong S, Guo J, Han X, et al. Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria. J Clin Endocrinol Metab. 2017. PMID: 28324025. doi:10.1210/jc.2016-2332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。